{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:12:56Z","timestamp":1777979576076,"version":"3.51.4"},"reference-count":33,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background\/Objectives: Ceftaroline fosamil (CFT) is a fifth-generation cephalosporin approved in Spain for skin and soft tissue infections and community-acquired pneumonia. CFT may also be useful against endovascular infections. This real-world study aimed to evaluate its effectiveness and safety in patients with Gram-positive (GP) infective endocarditis (IE). Methods: This observational, retrospective multicenter study enrolled adults with GP-IE treated with CFT for \u226548 h. Recruitment extended from CFT incorporation in participating hospitals through May 2024. Data were gathered on demographic, clinical, and microbiological variables, adverse effects, overall and IE-related mortality, relapses, and a composite unfavorable outcome. Results: Seventy-six patients (65.8% male) were enrolled, with a mean age of 68.9 \u00b1 12.8 years and an age-adjusted Charlson index of 4; 55.3% had previous moderate\/severe valvular heart disease, 35.5% had atrial fibrillation, 34.2% chronic heart failure, 17.1% chronic kidney disease, and 22.4% septic shock. IE was native valve-related in 53.9%, involving the aortic valve in 38.2% and the mitral in 30.3%. Staphylococcus aureus was isolated in 48.7%, being methicillin-resistant in 40.5% of cases. CFT was salvage therapy in 65.8% and combined with other antibiotics in 94.7%. Valve replacement was indicated in 64.5% but performed in only 67.3% of these. At six months, the adverse effect rate was 9.2%, overall crude mortality 38.2%, infection-related mortality 28.9%, and composite unfavorable outcome 40.1%. In multivariate analysis, mortality-related factors were age-adjusted Charlson index, septic shock, and methicillin-sensitive S. aureus. Conclusions: CFT showed favorable outcomes and acceptable safety in the real-life treatment of GP-related IE in clinically complex patients with high comorbidity and previous antibiotic therapy failures.<\/jats:p>","DOI":"10.3390\/antibiotics15050466","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:01:30Z","timestamp":1777975290000},"page":"466","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Experience of Ceftaroline Fosamil in Gram-Positive Infective Endocarditis: A Multicenter Real-World Observational Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1625-5038","authenticated-orcid":false,"given":"Daniel","family":"Arn\u00e9s-Garc\u00eda","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Calder\u00f3n-Parra","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Puerta de Hierro de Majadahonda, 28222 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Calvo-Salvador","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Puerta de Hierro de Majadahonda, 28222 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Herrero-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Unit, Complejo Hospitalario de Ja\u00e9n, 23007 Ja\u00e9n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8866-5194","authenticated-orcid":false,"given":"Svetlana","family":"Sadyrbaeva-Dolgova","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitario Virgen de las Nieves, Instituto de Investigaci\u00f3n Biosanitario de Granada (IBS-Granada), 18014 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-5728","authenticated-orcid":false,"given":"Carmen","family":"Hidalgo-Tenorio","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Universitario Virgen de las Nieves, Instituto de Investigaci\u00f3n Biosanitario de Granada (IBS-Granada), 18014 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jiph.2024.03.011","article-title":"Trends in epidemiology, surgical management, and prognosis of infective endocarditis during the XXI century in Spain: A population-based nationwide study","volume":"17","author":"Cobo","year":"2024","journal-title":"J. Infect. Public Health"},{"key":"ref_2","first-page":"728","article-title":"Epidemiology of infective endocarditis in Spain in the last 20 years","volume":"66","year":"2013","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_3","first-page":"141","article-title":"Increased incidence of infective endocarditis after the 2009 European Society of Cardiology guideline update: A nationwide study in the Netherlands","volume":"3","author":"Swaans","year":"2017","journal-title":"Eur. Heart J.\u2013Qual. Care Clin. Outcomes"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bloem, A., Bax, H.I., Yusuf, E., and Verkaik, N.J. (2021). New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081743"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"iv9","DOI":"10.1093\/jac\/dkq251","article-title":"Ceftaroline fosamil: A novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity","volume":"65","author":"Biek","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0213-005X(14)70153-3","article-title":"Pharmacokinetics and pharmacodynamics of ceftaroline","volume":"32","author":"Grau","year":"2014","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/cis563","article-title":"In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: A review of published studies and the AWARE Surveillance Program (2008\u20132010)","volume":"55","author":"Farrell","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jmii.2020.04.017","article-title":"In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012\u20132018","volume":"54","author":"Jean","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/jac\/dkv415","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: Individual patient data meta-analysis of randomized controlled trials","volume":"71","author":"Taboada","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/jac\/dkq254","article-title":"CANVAS 1: The first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1093\/jac\/dkw326","article-title":"Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: A matched cohort study","volume":"71","author":"Athans","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijantimicag.2019.06.025","article-title":"Off-label use of ceftaroline fosamil: A systematic review","volume":"54","author":"Pani","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ofx084","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: A systematic review","volume":"4","author":"Cosimi","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Oliva, A., Cogliati Dezza, F., Cancelli, F., Curtolo, A., Falletta, A., Volpicelli, L., and Venditti, M. (2023). New antimicrobials and new therapy strategies for endocarditis: Weapons that should be defended. J. Clin. Med., 12.","DOI":"10.3390\/jcm12247693"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijantimicag.2019.01.014","article-title":"Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience","volume":"53","author":"Destache","year":"2019","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s40121-024-01068-0","article-title":"Heartfelt impact: A descriptive analysis of ceftaroline-containing regimens in endocarditis due to methicillin-resistant Staphylococcus aureus","volume":"13","author":"Caniff","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s10096-022-04443-2","article-title":"Incidence and risk factors for mortality in patients treated with combined ceftaroline for Gram-positive infective endocarditis","volume":"41","author":"Suanzes","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s40121-023-00763-8","article-title":"Epidemiological changes and improvement in outcomes of infective endocarditis in Europe in the twenty-first century: An International Collaboration on Endocarditis (ICE) prospective cohort study (2000\u20132012)","volume":"12","author":"Ambrosioni","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1093\/eurheartj\/ehz620","article-title":"Clinical presentation aetiology outcome of infective endocarditis: Results of the ESC-EORPEURO-ENDO(European infective endocarditis) registry: A prospective cohort study","volume":"40","author":"Habib","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2174\/1574884715666210108103813","article-title":"Pre-clinical impact of the synergistic mechanism of daptomycin and ceftaroline on patients with methicillin-resistant Staphylococcus aureus bacteremia infections","volume":"16","author":"Eliazar","year":"2021","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/infdis\/jiaf245","article-title":"Time to reappraise the antibiotic treatment for methicillin-susceptible Staphylococcus aureus infective endocarditis: Data from the experimental model","volume":"232","author":"Gasch","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments","volume":"7","author":"McCreary","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.114.012461","article-title":"Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: A prospective study from the International Collaboration on Endocarditis","volume":"131","author":"Chu","year":"2015","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"106883","DOI":"10.1016\/j.ijantimicag.2023.106883","article-title":"Clinical results with the use of ceftaroline and ceftobiprole: Real-life experience in a tertiary care hospital","volume":"62","author":"Zampino","year":"2023","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Arn\u00e9s-Garc\u00eda, D., Pitto-Robles, I., Calder\u00f3n Parra, J., Calvo Salvador, M., Herrero Rodr\u00edguez, C., Gisbert, L., and Hidalgo-Tenorio, C. (2023). Ceft-to-ceft study: Real-life experience with ceftaroline and ceftobiprole in treatment of the principal infectious syndromes in a Spanish multicenter hospital cohort. Antibiotics, 12.","DOI":"10.3390\/antibiotics12121692"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s10741-025-10556-5","article-title":"Infective endocarditis complicated by shock: A systematic review and meta-analysis","volume":"30","author":"Mebazaa","year":"2025","journal-title":"Heart Fail. Rev."},{"key":"ref_28","first-page":"63","article-title":"Papel de la edad y las comorbilidades en la mortalidad de pacientes con endocarditis infecciosa","volume":"64","author":"Zarauza","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1016\/j.ijcard.2013.08.023","article-title":"Age adjusted Charlson co-morbidity index is an independent predictor of mortality over long-term follow-up in infective endocarditis","volume":"168","author":"Lu","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hidalgo-Tenorio, C., G\u00e1lvez, J., Mart\u00ednez-Marcos, F.J., Plata-Ciezar, A., De La Torre-Lima, J., L\u00f3pez-Cort\u00e9s, L.E., Noureddine, M., Reguera, J.M., Vinuesa, D., and Garc\u00eda, M.V. (2020). Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-4895-1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.cmi.2017.12.002","article-title":"Impact of Staphylococcus aureus phenotype and genotype on the clinical characteristics and outcome of infective endocarditis: A multicentre, longitudinal, prospective, observational study","volume":"24","author":"Ribera","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"ofab119","DOI":"10.1093\/ofid\/ofab119","article-title":"Outcomes and risk factors of septic shock in patients with infective endocarditis: A prospective cohort study","volume":"8","author":"Reviejo","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/cid\/ciad271","article-title":"The 2023 Duke-International Society for Cardiovascular Infectious Diseases criteria for infective endocarditis: Updating the modified Duke criteria","volume":"77","author":"Fowler","year":"2023","journal-title":"Clin. Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/5\/466\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:33:44Z","timestamp":1777977224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/5\/466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["antibiotics15050466"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15050466","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]}}}